Value-Dx: Point Prevalence Audit Survey
- Status:: Recruiting participants
Community acquired acute respiratory tract infection (CA-ARTI) in community care in Europe: point prevalence audit study (PPAS) of presentation and management.
This study aims to record information about patients who seek healthcare for CA-ARTI (e.g. acute cough, sore throat). This will help researchers benchmark patterns of testing and antibiotic prescribing in contrasting European settings simply by observing what happens now in routine care.
This PPAS study is part of a larger project called Value-Dx -the value of diagnostics to combat antimicrobial resistance by optimising antibiotic use- and makes up part of the clinical Work Package Four (WP4). The aim of Value-Dx is to transform clinical practice, improve patient outcomes, and combat antimicrobial resistance (AMR), through the widespread use of clinical and cost-effective innovative diagnostics strategies to achieve more personalised, evidence-based antibiotic prescription and use in community care settings.
The purpose of VALUE-Dx is to facilitate and accelerate the rigorous assessment and implementation of (new) diagnostic technologies into healthcare settings.
The project involves two clinical studies: PPAS, a Point-Prevalence Audit Study in winter season I (2019-2020); and, PRUDENCE, a platform randomised controlled trial of point of care diagnostics for enhancing the quality of antibiotic prescribing for community acquired acute respiratory tract infection in ambulatory care in Europe in winter seasons II (2020 -2021) and III (2021 – 2022).
|Study Design:||Clinical audit|
|Chief Investigator:||Prof. Chris Butler|